Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase... by Kowdley, Kris V, Dr, Lawitz, Eric, MD, Crespo, Israel, MD, Hassanein, Tarek, MD, Davis, Mitchell N, MD, DeMicco, Michael, MD, Bernstein, David E, MD, Afdhal, Nezam, MD, Vierling, John M, MD, Gordon, Stuart C, MD, Anderson, Jane K, PhD, Hyland, Robert H, DPhil, Dvory-Sobol, Hadas, PhD, An, Di, PhD, Hindes, Robert G, MD, Albanis, Efsevia, MD, Symonds, William T, PharmD, Berrey, M Michelle, MD, Nelson, David R, MD, Jacobson, Ira M, MD

Get full text

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT... by Kwo, Paul Y, Dr, Lawitz, Eric J, MD, McCone, Jonathan, MD, Schiff, Eugene R, Prof, Vierling, John M, Prof, Pound, David, MD, Davis, Mitchell N, DO, Galati, Joseph S, MD, Gordon, Stuart C, MD, Ravendhran, Natarajan, MD, Rossaro, Lorenzo, Prof, Anderson, Frank H, MD, Jacobson, Ira M, Prof, Rubin, Raymond, MD, Koury, Kenneth, PhD, Pedicone, Lisa D, PhD, Brass, Clifford A, MD, Chaudhri, Eirum, MD, Albrecht, Janice K, PhD

Get full text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection... by Lawitz, Eric, Prof, Gane, Edward, Prof, Pearlman, Brian, Prof, Tam, Edward, MD, Ghesquiere, Wayne, Prof, Guyader, Dominique, Prof, Alric, Laurent, MD, Bronowicki, Jean-Pierre, Prof, Lester, Laura, MSN, Sievert, William, Prof, Ghalib, Reem, MD, Balart, Luis, MD, Sund, Fredrik, MD, Lagging, Martin, Prof, Dutko, Frank, PhD, Shaughnessy, Melissa, MS, Hwang, Peggy, PhD, Howe, Anita Y M, PhD, Wahl, Janice, MD, Robertson, Michael, MD, Barr, Eliav, MD, Haber, Barbara, MD

Get full text

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR... by Lawitz, Eric, Prof, Poordad, Fred F, Prof, Pang, Phillip S, MD, Hyland, Robert H, DPhil, Ding, Xiao, PhD, Mo, Hongmei, PhD, Symonds, William T, PharmD, McHutchison, John G, MD, Membreno, Fernando E, MD

Get full text

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and trea... by Lawitz, Eric, Prof, Sulkowski, Mark S, Prof, Ghalib, Reem, MD, Rodriguez-Torres, Maribel, MD, Younossi, Zobair M, Prof, Corregidor, Ana, MD, DeJesus, Edwin, MD, Pearlman, Brian, Prof, Rabinovitz, Mordechai, Prof, Gitlin, Norman, MD, Lim, Joseph K, MD, Pockros, Paul J, MD, Scott, John D, MD, Fevery, Bart, MSc, Lambrecht, Tom, MSc, Ouwerkerk-Mahadevan, Sivi, PhD, Callewaert, Katleen, MSc, Symonds, William T, PharmD, Picchio, Gaston, PhD, Lindsay, Karen L, MD, Beumont, Maria, MD, Jacobson, Ira M, Prof

Get full text

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, doubl... by Lawitz, Eric, Prof, Lalezari, Jay P, MD, Hassanein, Tarek, Prof, Kowdley, Kris V, Prof, Poordad, Fred F, Prof, Sheikh, Aasim M, MBBS, Afdhal, Nezam H, Prof, Bernstein, David E, Prof, DeJesus, Edwin, MD, Freilich, Bradley, MD, Nelson, David R, Prof, Dieterich, Douglas T, Prof, Jacobson, Ira M, Prof, Jensen, Donald, Prof, Abrams, Gary A, MD, Darling, Jama M, MD, Rodriguez-Torres, Maribel, MD, Reddy, K Rajender, Prof, Sulkowski, Mark S, Prof, Bzowej, Natalie H, MD, Hyland, Robert H, DPhil, Mo, Hongmei, PhD, Lin, Ming, PhD, Mader, Michael, MS, Hindes, Robert, MD, Albanis, Efsevia, MD, Symonds, William T, PharmD, Berrey, Michelle M, MD, Muir, Andrew, Prof

Get full text